Neurogene Inc.

NASDAQ:NGNE

Biotechnology

Healthcare
$23.14 +2.47%

+$0.76 today

Market cap
$365.67M
Beta
2.04
P/E (TTM)
-7.1
EPS (TTM)
-$4.42
52W Low $14.65High $37.27

Volume 0.25M

Average 0.16M

NGNE Total Non-current Liabilities

All obligations due after more than one year.

Neurogene Inc.NASDAQ: NGNE

Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total non-current liabilities falls 31.0% from a year ago

Total non-current liabilities stood at $6.49M at the end of Q1 FY2026, down 31.0% from a year earlier and down 17.6% from the prior quarter. Over 3 fiscal years it compounded at +22.4% a year.

Context

  • Total non-current liabilities amounted to 2.5% of total assets at the end of Q1 FY2026, down 0.5 pp from a year earlier.
  • Total non-current liabilities increased in 1 of the last 3 fiscal years.

What to watch

Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -31.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.49M-17.6% QoQ
Last fiscal yearDec 2025
$7.31M-28.4% YoY
Year agoMar 2025
$9.41M-31.0% since
Total Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-31.0%——
1 year-28.4%——
3-year CAGR+22.4%——
5-year CAGR——
10-year CAGR——

Total Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
7.31M USD
Year-over-year change
-28.4%
4-year CAGR
-55.3%

Total Non-current Liabilities vs competitors

How NGNE compares with its peers on the latest reported figures

  • NGNE's Mar 2026 total non-current liabilities of $6.49M is the 6th highest of the 8 companies compared; the peer median is $28.2M.
  • Its year-over-year change of -31.0% is the lowest of 8, against a peer median of -7.5%.
  • Total non-current liabilities amounts to 2.5% of total assets for NGNE, versus a peer median of 12.2%.
NGNE Competitors Peer median
Total Non-current Liabilities for NGNE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALECAlector, Inc.Mar 2026$188.57M -7.5%-26.1%78.6%
MGTXMeiraGTx Holdings plcMar 2026$126.66M -8.6%+2.5%51.8%
TSHATaysha Gene Therapies, Inc.Jun 2026$57.19M -3.5%+3.7%12.2%
VYGRVoyager Therapeutics, Inc.Mar 2026$28.2M -30.1%+2.2%12.9%
FDMT4D Molecular Therapeutics, Inc.Mar 2026$17.67M -7.5%+4.9%3.4%
NGNENeurogene Inc.Mar 2026$6.49M -31.0%+22.4%2.5%
LXEOLexeo Therapeutics, Inc. Common StockMar 2026$4.67M -30.8%-70.1%1.9%
DSGNDesign Therapeutics, Inc.Mar 2026$2.2M +66.5%-40.4%1.0%
Peer median (excluding NGNE) $28.2M-7.5%+2.2%12.2%

Competitors are the stored peer set for NGNE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents70.54M82.02M148.21M136.59M103.85M
Short-term Investments0048.95M175.82M165.17M
Net Receivables790K0600K648K0
Inventory1.91M0000
Other Current Assets(1.2M)1.62M1.1M981K2.76M
Total Current Assets73.96M84.72M200.35M315.92M271.77M
Property, Plant & Equipment (Net)27.53M24.55M20.95M18.49M15.46M
Goodwill00000
Intangible Assets128K0000
Long-term Investments878K0000
Tax Assets00000
Other Non-current Assets(1.01M)01.27M1.31M1.37M
Total Non-current Assets27.53M24.55M22.23M19.81M16.83M
Total Assets101.49M109.27M222.57M335.73M288.6M
Account Payables5.63M625K2.6M1.34M1.95M
Short-term Debt1.22M003M3.06M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities132K167K6.71M1.43M6.32M
Total Current Liabilities10.86M6.65M22.97M15.16M16.41M
Long-term Debt00006.83M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities177.91M0203K769K479K
Total Non-current Liabilities182.51M3.99M13.58M10.2M7.31M
Total Liabilities193.36M10.64M36.55M25.36M23.72M
Common Stock1K0000
Retained Earnings(95.65M)(150.84M)(187.15M)(262.3M)(352.65M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity(91.88M)98.63M186.02M310.38M264.89M
Total Debt6.43M4.69M16.26M12.43M9.89M
Net Debt(64.11M)(77.33M)(131.96M)(124.16M)(93.95M)

Neurogene Inc.

NASDAQ:NGNE

Intrinsic Alpha fair value

Locked

Current Price

$23.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.